Journal of palliative medicine · 2025
Intranasal Ketamine for Episodic Neuropathic Pain in a Cancer Patient: A Case Report.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brown Kyle, Irshad Tayyaba
Аннотация
BACKGROUND: Ketamine is an N-methyl-D-aspartate receptor antagonist traditionally used for dissociative sedation that has also been used for the treatment of pain. Ketamine can have a higher bioavailability when administered intranasally.
OBJECTIVE: To present a case in which intranasal (IN) ketamine was used for unpredictable, episodic, cancer-related neuropathic pain.
CASE PRESENTATION: We present a 49-year-old patient with metastatic adenocarcinoma of the lung who presented to our outpatient palliative care clinic with uncontrolled severe episodic neuropathic pain of the lower extremity.
CASE MANAGEMENT: We prescribed compounded racemic ketamine 20-30 mg intranasally as needed at the onset of severe episodes of breakthrough pain, in addition to scheduled use of oral methadone and a buprenorphine patch for long-acting pain management.
CASE OUTCOME: The patient reported a decrease in frequency, intensity, and duration of episodic breakthrough pain with use of IN ketamine without any reported negative adverse effects.
CONCLUSION: Low-dose compounded racemic IN ketamine may be a useful and safe adjunct in alleviating severe breakthrough pain in cancer patients in the outpatient setting.
OBJECTIVE: To present a case in which intranasal (IN) ketamine was used for unpredictable, episodic, cancer-related neuropathic pain.
CASE PRESENTATION: We present a 49-year-old patient with metastatic adenocarcinoma of the lung who presented to our outpatient palliative care clinic with uncontrolled severe episodic neuropathic pain of the lower extremity.
CASE MANAGEMENT: We prescribed compounded racemic ketamine 20-30 mg intranasally as needed at the onset of severe episodes of breakthrough pain, in addition to scheduled use of oral methadone and a buprenorphine patch for long-acting pain management.
CASE OUTCOME: The patient reported a decrease in frequency, intensity, and duration of episodic breakthrough pain with use of IN ketamine without any reported negative adverse effects.
CONCLUSION: Low-dose compounded racemic IN ketamine may be a useful and safe adjunct in alleviating severe breakthrough pain in cancer patients in the outpatient setting.